Calendar

Week of Apr 27, 2026

Apr 30, 2026phase 1 completion113d agoBarts Charity — undisclosed Covid-19 vaccine (Phase I Trial Completion)undisclosed Covid-19 vaccine

Therapy area: Cardiovascular. Indication: Cardiovascular Disease, Endothelial Dysfunction

full page →undisclosed Covid-19 vaccine →source: globaldata

Apr 30, 2026phase 1 completion113d agoInsignis Therapeutics Inc — HLK-0006 (Phase I Trial Completion)HLK-0006

Therapy area: Immunology. Indication: Anaphylaxis, Food Allergy, Peanut Allergy

full page →HLK-0006 →source: globaldata

Apr 30, 2026phase 1 initiation113d agoEgyptian International Pharmaceuticals Industries Co SAE — enoxaparin sodium biosimilar (Phase I Trial Initiation)enoxaparin sodium biosimilar

Therapy area: Cardiovascular. Indication: Acute Coronary Syndrome, Congestive Heart Failure (Heart Failure), Deep Vein Thrombosis (DVT), Myocardial Infarction, Pulmonary Embolism, Thromboembolic Disease, Thromboembolism, Thrombosis, Unstable Angina, Venous (Vein) Thrombosis, Venous Thromboembolism

full page →enoxaparin sodium biosimilar →source: globaldata

Apr 30, 2026phase 1 initiation113d agoFirst Affiliated Hospital of Bengbu Medical University — Loberamisal (Phase I Trial Initiation)Loberamisal

Therapy area: Cardiovascular. Indication: Acute Ischemic Stroke

full page →Loberamisal →source: globaldata

Apr 30, 2026phase 1 initiation113d agoGilead Sciences Inc — GS-1701 (Phase I Trial Initiation)GS-1701

Therapy area: Infectious Disease. Indication: Unspecified Infectious Diseases

full page →GS-1701 →source: globaldata

Apr 30, 2026phase 1 initiation113d agoBio-Innova Co Ltd — dapagliflozin (Phase I Trial Initiation)DAPAGLIFLOZIN

Therapy area: Cardiovascular, Genito Urinary System, Metabolic Disorders. Indication: Cardiovascular Risk Factors, Diabetic Nephropathy, Type 1 Diabetes (Juvenile Diabetes), Type 2 Diabetes

full page →DAPAGLIFLOZIN →source: globaldata

Apr 30, 2026phase 1 initiation113d agoNanjing IASO Biotherapeutics Co Ltd — IASO-782 (Phase I Trial Initiation)IASO-782

Therapy area: Immunology. Indication: Systemic Lupus Erythematosus

full page →IASO-782 →source: globaldata

Apr 30, 2026phase 1 initiation113d agoThe National Institute of Allergy and Infectious Diseases — dasatinib (Phase I Trial Initiation)DASATINIB

Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

full page →DASATINIB →source: globaldata

Apr 30, 2026phase 1 2 completion113d agoDuke University — deferiprone (Phase I/II Trial Completion)deferiprone

Therapy area: Cardiovascular, Central Nervous System. Indication: Cerebral Aneurysms, Dementia, Stroke, Subarachnoid Hemorrhage

full page →deferiprone →source: globaldata

Apr 30, 2026phase 1 2 completion113d agoUniversity Hospital Geneva — verteporfin (Phase I/II Trial Completion)verteporfin

Therapy area: Dermatology, Infectious Disease, Oncology. Indication: Melanoma, Scar, Surgical Wound Infections

full page →verteporfin →source: globaldata

Apr 30, 2026phase 1 2 completion113d agoImplicit Bioscience Ltd — Atibuclimab (Phase I/II Trial Completion)Atibuclimab

Therapy area: Cardiovascular. Indication: Acute Decompensated Heart Failure, Congestive Heart Failure (Heart Failure)

full page →Atibuclimab →source: globaldata

Apr 30, 2026phase 1 2 completion113d agoEyebiotech Ltd — MK-8748 (Phase I/II Trial Completion)MK-8748

Therapy area: Ophthalmology. Indication: Age Related Macular Degeneration, Branch Retinal Vein Occlusion, Diabetic Macular Edema, Macular Edema, Wet (Neovascular / Exudative) Macular Degeneration

full page →MK-8748 →source: globaldata

Apr 30, 2026phase 2 completion113d agoUsynova Pharmaceuticals Ltd — UA-021 (Phase II Trial Completion)UA-021

Therapy area: Immunology. Indication: Plaque Psoriasis (Psoriasis Vulgaris), Psoriasis

full page →UA-021 →source: globaldata

Apr 30, 2026phase 2 completion113d agoZhejiang Provincial People's Hospital — telitacicept (Phase II Trial Completion)telitacicept

Therapy area: Immunology. Indication: Rheumatoid Arthritis

full page →telitacicept →source: globaldata

Apr 30, 2026phase 2 completion113d agoQinghai Provincial Xining Third People's Hospital — amoxicillin (Phase II Trial Completion)amoxicillin

Therapy area: Gastrointestinal, Infectious Disease. Indication: Gastritis, Helicobacter pylori Infections

full page →amoxicillin →source: globaldata

Apr 30, 2026phase 2 completion113d agoGuy's and St Thomas' NHS Foundation Trust — autologous regulatory T cells (Phase II Trial Completion)autologous regulatory T cells

Therapy area: Genito Urinary System, Immunology. Indication: End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Kidney Transplant Rejection

full page →autologous regulatory T cells →source: globaldata

Apr 30, 2026phase 2 completion113d agoMerck & Co Inc — tulisokibart (Phase II Trial Completion)tulisokibart

Therapy area: Immunology, Respiratory. Indication: Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Systemic Sclerosis (Scleroderma)

full page →tulisokibart →source: globaldata

Apr 30, 2026phase 2 completion113d agoGerman Sport University Cologne — polyphenol-rich cocoa extract (Phase II Trial Completion)polyphenol-rich cocoa extract

Therapy area: Cardiovascular. Indication: Idiopathic (Essential) Hypertension

full page →polyphenol-rich cocoa extract →source: globaldata

Apr 30, 2026phase 2 completion113d agoMedanta - The Medicity — centhaquine citrate (Phase II Trial Completion)centhaquine citrate

Therapy area: Cardiovascular, Other Diseases. Indication: Hemorrhagic Shock, Injury, Trauma

full page →centhaquine citrate →source: globaldata

Apr 30, 2026phase 2 completion113d agoShenzhen Eye Hospital — umbilical cord mesenchymal stem cells derived apoptotic vesicles (Phase II Trial Completion)umbilical cord mesenchymal stem cells derived apoptotic vesicles

Therapy area: Ophthalmology. Indication: Keratoconjunctivitis Sicca (Dry Eye)

full page →umbilical cord mesenchymal stem cells derived apoptotic vesicles →source: globaldata

Apr 30, 2026phase 2 completion113d agoNigde Omer Halisdemir University — ozonated oil (Phase II Trial Completion)ozonated oil

Therapy area: Dermatology, Gastrointestinal, Immunology. Indication: Inflammation, Inguinal Hernia, Wounds

full page →ozonated oil →source: globaldata

Apr 30, 2026phase 2 completion113d agoCancer Institute and Hospital Chinese Academy of Medical Sciences — lenvatinib (Phase II Trial Completion)lenvatinib

Therapy area: Cardiovascular, Oncology. Indication: Hepatocellular Carcinoma, Thrombosis, Venous (Vein) Thrombosis

full page →lenvatinib →source: globaldata

Apr 30, 2026phase 2 completion113d agoMedical University of Gdansk — apixaban (Phase II Trial Completion)apixaban ODT

Therapy area: Cardiovascular, Oncology. Indication: Diffuse Large B-Cell Lymphoma, Hematological Tumor, Leukemia, Lymphoma, Multiple Myeloma (Kahler Disease), Myeloproliferative Disorders, Pulmonary Embolism, Thromboembolic Disease, Venous Thromboembolism

full page →apixaban ODT →source: globaldata

Apr 30, 2026phase 2 completion113d agoNeurodawn Pharmaceutical Co Ltd — Loberamisal (Phase II Trial Completion)Loberamisal

Therapy area: Cardiovascular. Indication: Acute Ischemic Stroke, Cerebral Infarction (Brain Infarction)

full page →Loberamisal →source: globaldata

Apr 30, 2026phase 2 completion113d agoSohag University — ephedrine (Phase II Trial Completion)ephedrine

Therapy area: Cardiovascular. Indication: Hypotension

full page →ephedrine →source: globaldata

Apr 30, 2026phase 2 completion113d agoNational Institutes of Health — metformin hydrochloride ER (Phase II Trial Completion)metformin hydrochloride ER

Therapy area: Cardiovascular, Genito Urinary System, Infectious Disease. Indication: Acute Renal Failure (ARF) (Acute Kidney Injury), Sepsis, Septic Shock

full page →metformin hydrochloride ER →source: globaldata

Apr 30, 2026phase 2 completion113d agoCurtin University — influenza vaccine (Phase II Trial Completion)influenza vaccine

Therapy area: Cardiovascular. Indication: Myocardial Infarction

full page →influenza vaccine →source: globaldata

Apr 30, 2026phase 2 completion113d agoRenji Hospital — norepinephrine (Phase II Trial Completion)norepinephrine

Therapy area: Genito Urinary System, Immunology. Indication: Delayed Graft Function (DGF), End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)

full page →norepinephrine →source: globaldata

Apr 30, 2026phase 2 completion113d agoNanjing First Hospital — amoxicillin (Phase II Trial Completion)amoxicillin

Therapy area: Infectious Disease. Indication: Helicobacter pylori Infections

full page →amoxicillin →source: globaldata

Apr 30, 2026phase 2 completion113d agoDutch Heart Foundation — ghrelin (Phase II Trial Completion)ghrelin

Therapy area: Cardiovascular. Indication: Acute Ischemic Stroke, Ischemic Stroke

full page →ghrelin →source: globaldata

Apr 30, 2026phase 2 completion113d agoSunstar Inc — SSJG-009 (Phase II Trial Completion)SSJG-009

Therapy area: Immunology. Indication: Inflammation

full page →SSJG-009 →source: globaldata

Apr 30, 2026phase 2 completion113d agoInstituto de Investigacion sanitaria de Santiago de Compostela — Vacucis (Phase II Trial Completion)Vacucis

Therapy area: Infectious Disease, Mouth and Dental Disorders. Indication: Candidiasis, Xerostomia

full page →Vacucis →source: globaldata

← prev

page 3 of 3

Week of Apr 27, 2026